Table of Contents

Exhibit 99.1

Contents

Table of Contents

Independent Auditor’s Report

To the Members of Molecular Profiles Limited

We have audited the accompanying financial statements of Molecular Profiles Limited, which comprise the balance sheets as of July 31, 2013 and 2012, and the related profit and loss account, and related notes for the years then ended.

Management’s responsibility for the financial statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law); this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor’s responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Molecular Profiles Limited as of July 31, 2013 and 2012, and the results of its operations for the years then ended in accordance with United Kingdom Generally Accepted Accounting Practice applicable to Smaller Entities.

Emphasis of Matter – accounting framework

The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United Kingdom applicable for smaller entities. These standards differ in certain respects from accounting principles generally accepted in the United States of America. Further information is presented in Notes 20 – 24 to the financial statements. Our opinion is not modified with respect to this matter.

Grant Thornton UK LLP

Chartered Accountants

Birmingham, United Kingdom

21 November 2013

1

Table of Contents

Profit and Loss Account

For the Year Ended 31 July 2013

The notes on pages 4 to 13 form part of these financial statements.

2

Table of Contents

Balance Sheet

As at 31 July 2013

The financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

The financial statements were approved and authorized for issue by the board and were signed on its behalf by

/s/ Nikin Patel

Nikin Patel

Director

The notes on pages 4 to 13 form part of these financial statements.

3

Table of Contents

The financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006, ‘The Small Companies and Groups (Accounts and Directors’ Report) Regulations 2008’ and with the Financial Reporting Standard for Smaller Entities (effective April 2008).

The financial statements have been prepared under the historical cost convention. The following principal accounting policies have remained unchanged from the prior year.

The financial statements have been prepared on a going concern basis. The directors are pleased to report that the company has sufficient cash resources along with bank facilities to meet its working capital requirements for the foreseeable future.

The turnover shown in the profit and loss account represents the invoiced value of work carried out during the year, exclusive of Value Added Tax. Where turnover relates to the provision of a service such as testing, revenue is recognized as contract activity progresses.

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

The tax benefit recognized in the Profit and Loss account comprises the sum of deferred tax and current tax.

Current income tax assets and/or liabilities comprise those obligations to, or claims from, fiscal authorities relating to the current or prior reporting periods, that are unpaid at the reporting date. Current tax is payable on taxable profit, which differs from profit or loss in the financial statements. Calculation of current tax is based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognized in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more, or a right to pay less or to receive more tax. Deferred tax assets are recognized when it is more likely than not that they will be recovered. Deferred tax is measured on a non-discounted basis using rates of tax that have been enacted or substantively enacted by the balance sheet date.

Research and development expenditure is charged to the Profit and Loss account in the period in which it is incurred.

Grant income of a capital nature is accounted for as either a deduction against the amount of the grant from

4

Table of Contents

the purchase price of the related asset, with a consequent reduction in the annual charge for depreciation, or by treating the amount of the grant as deferred income which is credited to the profit and loss account by installments over the expected useful economic life of the related asset on a basis consistent with the depreciation policy.

Grant income of a revenue nature is credited to the profit and loss account so as to match it with the expenditure to which it is intended to contribute.

The company provides access to a group personal pension plan which is administered by Standard Life. Total contributions payable at the year-end are £10,092 (2012: £9,823).

The percentage of turnover that is attributable to markets outside the United Kingdom is 82.0% (2012 - 85.0%).

The operating profit is stated after charging/(crediting):

Remuneration in respect of directors was as follows:

During the year retirement benefits were accruing to 2 directors (2012 - 2) in respect of defined contribution pension schemes.

5

Table of Contents

Factors affecting tax charge for the year

The tax assessed for the year is lower than (2012 - lower than) the standard rate of corporation tax in the UK of 23.67% (2012 - 20.00%). The differences are explained below:

6

Table of Contents

All amounts shown under debtors fall due for payment within one year.

7

Table of Contents

The bank loans totaling £2,500,000 at inception represent three facilities which are repayable by monthly instalments, with one starting to be repaid from January 2013, and the other 2 due to commence in October 2013. All facilities are due for repayment 15 years from the date of drawdown. Two of the facilities bear interest at 1.95% and 2.55% above base rate per annum respectively. The third facility is a fixed rate agreement bearing interest at 3.52% per annum. The loans are secured on mortgaged properties or an unlimited debenture over other assets of the company.

The provision for deferred taxation is made up as follows:

8

Table of Contents

Share options

At 31 July 2013 and at 31 July 2012, four employees held 1,004 options over ordinary shares exercisable at £95.30 per share and 342 options exercisable at £70.00 per share. The share options are only exercisable in the event of a sale or listing. These options were granted on 13 April 2006.

The capital redemption reserve is a non-distributable class of reserve.

Amounts payable to companies controlled by the following directors and shareholders for their services provided to the business in the year were:

At 31 July 2013, the company owed a company controlled by M C Davies £292,668 (2012: £63,528) and P M Williams £nil (2012: £nil) in respect of these services.

In September 2013, the company was acquired by Columbia Laboratories Inc. (see note 19). At 31 July 2013, there was a balance payable by Columbia Laboratories Inc. to Molecular Profiles Limited of £17,498.

9

Table of Contents

There were no capital commitments at 31 July 2013 or 31 July 2012.

There were no contingent liabilities at 31 July 2013 or 31 July 2012.

By virtue of the spread of shareholdings there is no one controlling party.

On 12 September 2013, the entire issued share capital of the company was acquired by Columbia Laboratories Inc., a company incorporated in the United States of America.

10

Table of Contents

The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United Kingdom (“UK GAAP”); specifically, the financial reporting framework that has been applied in their preparation is applicable law and the Financial Reporting Standard for Smaller Entities (“FRSSE”). For the purpose of the financial statements of Molecular Profiles Limited, there are no significant differences between the actual results reported for the years ended July 31, 2013 and July 31, 2012 and the results which would have been reported for those periods had the FRSSE not been applied.

These standards differ in certain respects from accounting principles generally accepted in the United States of America (“US GAAP”). Differences which have an effect on the consolidated net income, shareholders’ equity and financial position of the Company are set out below

Effect of differences between UK GAAP and US GAAP on net income after tax:

Effect of differences between UK GAAP and US GAAP on net equity:

Under UK GAAP, the Company matches income to the related expenses associated with the Grant for Business Investment (GBI) grant. Under US GAAP, revenue is recognized under the proportional performance method over the expected life of the contractual agreement.

Under UK GAAP, the Company matches income to the related expenses associated with the Regional Growth Fund (RGF) grant. Under US GAAP, revenue is recognized under the proportional performance method over the expected life of the contractual agreement. The Company is recognizing revenue over the performance period based on the overall risks associated with the grant.

11

Table of Contents

In association with the grant under UK GAAP, the Company recorded land at historic cost less the grant income associated to the land. Under US GAAP, land is stated at cost and cannot be offset by the income attributable to the land.

Under UK GAAP, deferred tax assets are recognized only to the extent that, on the basis of all available evidence, it is considered that there will be sufficient future profits from which the reversal of the timing losses can be deducted. There is a general acceptance that an entity would look out between 1-3 years when considering future profitability to evaluate the probability of realizing the assets. Under US GAAP, there is no accepted cap on the look-out period when the company had a history of profitability. Additionally positive and negative evidence is weighted in determining the recognition of deferred tax assets.

Under US GAAP, deferred taxes are presumptively recognized on unremitted earnings related to foreign countries unless there is sufficient evidence that the country will invest the undistributed earnings indefinitely.

The accompanying statements of stockholder’s equity and comprehensive income set out below for illustrative purposes, is presented using the captions under US GAAP.

Under ASC 230, “Statement of Cash Flows,” it is required to present cash flows from operating, investing, and financing activities. Set out below, for illustrative purposes, is the consolidated statement of cash flows presented using the captions under US GAAP.

12

Table of Contents

In addition to the differences between UK GAAP and US GAAP related to the recognition and measurement of transactions by the Company, there are also a number of differences in the manner in which items are classified in the consolidated profit and loss account and consolidated balance sheet. These classification differences have no impact on net income or shareholders’ equity.

Under UK GAAP, the balance sheets are presented in ascending order of liquidity, whereas under US GAAP assets are presented in descending order of liquidity. Also under UK GAAP, the balance sheet is ordinarily analyzed between net assets and shareholders’ funds. Under US GAAP, the analysis is between total assets and total liabilities plus shareholder’s equity.

Following the balance sheet date, on September 12, 2013, the entire issued share capital of the Company was acquired by Columbia Laboratories Inc., a company incorporated in the United States of America.

As a result of this transaction, the stock-based awards to employees and directors in 2006, 2012 and 2013 vested. This will result in a charge to the Statement of Operations in the year ended July 31, 2014 of $147,386, together with related tax effects thereof.

13